Enzyme Replacement Therapy Market Strategies and Forecasts to 2026

Enzyme Replacement Therapy Market Size,
Share, Trend, Outlook, Future Growth
Analysis And Synthesis 2018 - 2026
Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the
deficiency of enzymes that causes a specific disease condition called lysosomal storage disease. Enzyme
replacement therapy is used in Fabry Disease, Gaucher disease, lysosomal acid lipase deficiency,
mucopolysaccharidosis, Hunter syndrome, and Pompe disease. Enzymes are obtained from sources such
as human cells, animal cells, and recombinant DNA technology. Enzyme replacement, although does not
provide permanent cure, helps prevents permanent damage to the body caused due to deficiency of a
specific enzyme. Treatment consists of weekly or monthly doses depending upon the disease. For
instance, in order to address enzyme deficiency in Gaucher disease, modified version of
glucocerebrosidase is administered intravenously every two weeks. Enzyme replacement is associated
with fewer side effects than other treatment methods. However, enzyme replacement therapy may be
inconvenient for some patients such as children and geriatric population due to intravenous
administration. It may result in local infusion reaction or hypersensitive reactions in the form of local
rash, fever, edema, bronchospasm or hypotension.
Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1752
Market Dynamics
Although lysosomal storage disease is a rare disorder, a significant number of people are affected with
this disease. According to study published in Molecular Genetics and Metabolism Reports in December
2017, lysosomal storage disease has incidence rate of 1 in 4000 to 1 13,000 live births. Lysosomal
storage disease consists of 60 genetic abnormalities with problematic enzyme function. Being an orphan
disease condition, regulatory agencies offer the benefit of rapid approval and ease in approval process.
This in turn, is expected to expand the overall enzyme replacement therapy market with introduction of
new therapies by various key players. For instance, in November 2017, The FDA approved Mepsevii
(vestronidase alfa), which is first authorized treatment for pediatric and adult patients suffering from an
inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII). FDA granted Mepsevii
with fast-track approval and orphan drug status to incentivize the development. Financial help by NGOs
such as National Gaucher Society help patient receive enzyme replacement therapy that are costly.
Regional Insights
On the basis of geography, the global enzyme replacement therapy market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to
lead the market during forecast period, followed by Europe. According to study published in journal
Hematology, in March 2017, incidence of Gaucher Disease in the general population varied from 0.39 to
5.80 per 100?000, and its prevalence varied from 0.70 to 1.75 per 100?000. Ease in access and
government support for research and development is expected to aid growth of the enzyme replacement
therapy market.
Report includes chapters which deeply display the following deliverable about industry:
• Enzyme Replacement Therapy Market Research Objective and Assumption
• Enzyme Replacement Therapy Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Enzyme Replacement Therapy Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Enzyme Replacement Therapy Market, By Regions
• Enzyme Replacement Therapy Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Enzyme Replacement Therapy Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Enzyme Replacement Therapy Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Enzyme Replacement Therapy Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Competitive Landscape
Key players operating in the global enzyme replacement therapy market include Shire plc, Amicus
Therapeutics, Genzyme Corporation, Pfizer Inc., BioMarin Pharmaceutical, Inc., Sigma-Tau
Pharmaceuticals, Inc., Essential Pharmaceuticals Limited, Merck KGa, and AbbVie Inc.
Market Taxonomy
On the basis of enzyme type, the global enzyme replacement therapy market is segmented into -:
Agalsidase Beta
Velaglucerase Alfa
Alglucosidase Alfa
On the basis of indication, the global enzyme replacement therapy market is segmented into -:
Fabry Disease
Gaucher Disease
Pompe Disease
Scheie Syndrome
Hunter Disease
Maroteaux-Lamy Syndrome
Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoinginsight/enzyme-replacement-therapy-market-1752
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the deficiency of enzymes that causes a specific disease condition called lysosomal storage disease.